BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study
Stem cell mobilization for bone marrow transplantation estimated to be> $360 million market in the U.S. (> $500 million globally), with consistent...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Bone Marrow Transplant | Drugs & Pharmacology | New Drug Applications | Stem Cell Therapy | Stem Cells | Study | Transplants